Please assess the completion status of the following clinical trial:

Trial Title: Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male patients, 18 to 80 years (inclusive) of age at randomisation~* CAC score of 100 to 3500 AU (Agatston Units) inclusive within a 3-week period prior to randomisation as measured by a multi-detector CT scanner~* Patients who are EITHER ≥ 55 years OR have a history of diabetes mellitus at randomisation~* Patients on HD for ≥ 6 months prior to randomisation~* Willing and able to understand and sign the informed consent~Exclusion Criteria:~* Scheduled date for kidney transplant from a known living donor~* Weight above 300 lbs (136 kg)~* Hospitalisation in the previous 3 months prior to randomisation for unstable angina, MI, stroke, transient ischaemic attack, amputation or peripheral or coronary bypass surgery~* History of unstable heart failure in the previous 3 months, defined as an unplanned presentation to a hospital or dialysis treatment facility with signs/symptoms of acute pulmonary edema and requiring ultrafiltration therapy~* History of cancer that has been in remission for \< 5 years prior to randomisation. A history of basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin is allowed~* Pregnant or trying to become pregnant, currently breast-feeding, or of child-bearing potential (including peri-menopausal women who have had a menstrual period within one year) and not willing to practice birth control using a double barrier method (criteria apply to women only) at least 30 days post last dose of study medication~* Hypocalcaemia defined as a serum calcium below 8.0 mg/dL (or 2.0 mmol/L) for the serum calcium most proximal to screening per patient's medical records~* Extreme elevation in serum phosphorous, defined as a serum phosphorous above 10 mg/dL (or 3.23 mmol/L) within the last 2 months proximal to screening per patient's medical records~* Uncontrolled hypertension defined as any 2 or more consecutive post-dialysis diastolic blood pressure (DBP) \> 100 mmHg within the last 2 months proximal to screening expected survival \< 2 years in the Investigator's medical opinion~* Known active drug or alcohol abuse within 1 year of randomisation~* Use of other investigational drugs within 30 days of randomisation~* Non-compliance with dialysis treatment which, in the opinion of the Investigator, evidenced by either repeated missed dialysis treatments or significant non-compliance with the patient's medication regimen~* Inability to comply with all required study procedures and schedule, inability to speak and read in the protocol-derived language of that patient's clinical site, or unwillingness or inability to give written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- SNF472 300 mg (Type: EXPERIMENTAL): Dose 1 arm (300 mg): 1 vial of physiological saline and 1 vial of active (10 mL SNF472 at 30 mg/mL)
- SNF 472 600 mg (Type: EXPERIMENTAL): Dose 2 arm (600 mg): 2 vials of active (10 mL SNF472 at 30 mg/mL)
- Matching Placebo (Type: PLACEBO_COMPARATOR): Placebo arm: 2 vials of physiological saline

Based on this trial design, predict the completion outcome and termination type (if applicable).